A Study to Develop a Device to Aid in the Administration of Corticosteroid Nasal Spray to Improve Efficacy

Abstract

Allergic rhinitis and chronic rhinosinusitis represent conditions stemming from two pivotal pathophysiological factors: hypersensitivity reactions and inflammation.(Bjermer et al., 2019; Liva et al., 2021; Nur Husna et al., 2022) Patients afflicted with chronic rhinosinusitis experience symptoms that profoundly impact their quality of life. (Sapsaprang et al., 2015) Consequently, treatment guidelines consistently advocate for the utilization of intranasal corticosteroids (INC) in cases of severe disease or disruptive symptoms. (Bousquet et al., 2020; Dykewicz et al., 2020; Emeryk et al., 2019; Scadding et al., 2017) However, clinical evidence suggests that during episodes of nasal mucosal inflammation, tissue edema can hinder the comprehensive dispersion of INC particles into deeper nasal recesses, thus impeding their therapeutic reach to affected regions. (Abdelhafeez, 2022; Rollema et al., 2022; Sher & Ross, 2014) Conversely, presently available nasal spray formulations, particularly aqueous solutions commonly employed in Thailand, exhibit limitations in achieving efficient particle dispersion. Consequently, the effective delivery of INC is significantly contingent upon proper medication administration techniques, including bottle priming and synchronized inhalation during actuation. Literature reviews have divulged that many INC users frequently mismanage or inefficiently apply the medication, particularly during the actuation process.(Al-Rasheedi, 2023; May & Dolen, 2019) Common issues include improper alignment of the nasal spray nozzle, inadequate force exerted during actuation, and failure to synchronize inhalation with medication release, collectively contributing to suboptimal treatment outcomes.